Management of Muscle Invasive Bladder Cancer

Miss Sanchia S. Goonewardene, MBChB (Hons.Clin.Sc), BMedSc(Hons), PGCGC, Dip.SSc, MRCS (Ed and Eng) MPhil. Sanchia Goonewardene qualified from Birmingham Medical School with Honours in Clinical Science and a BMedSc Degree in Medical Genetics and Molecular Medicine. She has a specific interest in academia during her spare time, with over 627 publications to her name with 2 papers as a number 1 most cited in fields (Biomedical Library), and has significantly contributed to the Urological Academic World- she has since added a section to the European Association of Urology Congress on Prostate Cancer Survivorship and Supportive Care and is an associate member of an EAU guidelines panel on Chronic Pelvic Pain. She has been the UK lead in an EAU led study on Salvage Prostatectomy. She has also contributed to the BURST IDENTIFY study as a collaborator. Her background with research entails an MPhil, the work from which went on to be drawn up as a document for PCUK then, NICE endorsed. She gained funding from the Wellcome Trust for her Research Elective. She is also an Alumni of the Urology Foundation. She is an Editorial board member of the World Journal of Urology and was invited to be Guest Editor for a Special Issue on Salvage Therapy in Prostate Cancer. She is also a review board member for BMJ case reports. Most recently she has been a ICS Ambassador, ICS Mentor, ICS abstract reviewer and has been a Session Chair at YAU-ERUS, where she has presented her work. Mr Hanif Motiwala , MB, BS, MS, FRCS (Edin)), FRCS (Urol),. Mr Hanif Motiwala is a Senior Pelvic and Reconstructive Urologist working at Southend University Hospital and Essex Cancer Centre. He has spent over 25 years in Pelvic surgery with 1000+ pelvic operations comprising both radical and salvage surgeries. He is well known to the urology community worldwide. He was Professor of Urology in India and has also served as an FRCS Urol Examiner. He has been training Programme Director for the London Deanery, Imperial Rotation, and was well liked by all of his trainees. He has also been a Lecturer for Institute of Urology and Oxford Trainees. He has extensive exposure to senior leadership roles within healthcare provision and professional institutions including Associate Medical Director and Chairman of the surgical division at Wexham Park Hospital. He also has a strong track record of achieving clinical targets within tightly controlled budgets, developing innovative strategies to improve patient care and optimise use of resources, for which he received a Bronze Award. He is a dedicated and committed surgeon, utilising teaching, surgical and medical skills for the greater good through international voluntary work, building capability and skills in reconstructive surgery in India and Africa. He was conferred a position as Visiting Professor - University of Khartoum, Sudan, 2009 in recognition of voluntary work in Sudan, conducting final Urology Examinations to train qualified surgeons, providing training to surgeons in reconstruction and carrying out complex surgery. His other interests are in area of Reconstruction and Andrology. Prof Raj Persad, MB, BS, ChM, FRCS (Eng), FRCS (Urol), FEBU. Raj Persad, appointed in 1996, is a Consultant Urological Surgeon and Andrologist in Bristol. In his clinical role, he is one of the most experienced pelvic cancer surgeons in the UK and was one of the first in the UK to practice female neobladder reconstruction following cystectomy for invasive bladder cancer. He has subspecialised over many years in precise surgical techniques which improve both oncologic and functional outcomes. This includes techniques ranging from 1) the use of the Da Vinci Robot for performing Robot Assisted Laparoscopic Radical Prostatectomy, 2) High Intensity Focused Ultrasound for minimally invasive non-surgical treatment of prostate cancer and 3) Rectal Spacer and

1. Introduction to muscle invasive bladder cancer.- 2. Epidemiology and risk factors in muscle invasive bladder cancer.- 3. The molecular basis of muscle invasive bladder cancer.- 4. Histological variants in MIBC - squamous cell and squamous differentiation.- 5. Histological variants in muscle invasive bladder cancer - adenocarcinoma.- 6. Histological variants in muscle invasive bladder Cancer - sarcomatoid cancer.- 7. MIBC Carcinosarcoma.- 8. Muscle invasive bladder cancer- small cell.- 9. MIBC plasmacytoid.- 10. MIBC  and micropapillary bladder cancer.- 11. MIBC bladder cancer assessment and diagnosis.- 12. A systematic review on blue light cystoscopy in bladder cancer diagnostics.- 13. A systematic review on the staging conundrum in bladder cancer.- 14. Current state of investigations and limitations in muscle invasive bladder cancer.- 15. Risk stratification in bladder cancer.- 16. Preventative measures for those with high risk MIBC.- 17. Bladder cancer risk post pelvic irradiation.- 18. A systematic review on bladder preservation strategies and MIBC.- 19. Partial cystectomy.- 20. Muscle invasive bladder cancer and neoadjuvant chemotherapy.- 21. Controversies in clinical effectiveness of neoadjuvant chemotherapy.- 22. Trimodal therapy in bladder cancer.- 23. Systematic review on trimodal therapy in bladder cancer.- 24. Trimodal therapy - a systematic review.- 25. Reviews related to trimodal therapy for MIBC.- 26. Radical cystectomy lap open robotic.- 27. Prostate sparing cystectomy - a systematic review.- 28. A systematic review on nerve sparing cystoprostatectomy.- 29. MIBC - orthotopic vs ileal conduit.- 30. MIBC - a systematic review on orthotopic neobladder vs. ileal conduit.- 31. MIBC and radical cystectomy in the elderly.- 32. MIBC radical radiotherapy.- 33. MIBC - quality of life with urinary diversion.- 34. Neoadjuvant chemotherapy for muscle invasive bladder cancer.- 35. Muscle invasive bladder cancer and the staging conundrum.- 36. Radical cystectomy outcomes.- 37. Muscle Invasive bladder cancer and neoadjuvant chemotherapy.- 38. Muscle invasive bladder cancer and the staging conundrum.- 39. Physical pre-habilitation prior to radical cystectomy.- 40. Exercise therapy pre surgery.- 41. Patient fitness for surgery.- 42. CPEX testing prior to major urological surgery.- 43. Cardio-pulmonary exercise testing and major urological surgery.- 44. Robotic radical cystectomy and enhanced recovery.- 45. The robotic approach to redo surgery.- 46. Robotic cystectomy and intracorporeal neobladder formation.- 47. Secondary pelvic malignancies and bladder cancer.- 48. Organ sparing cystectomy.- 49. Robotic radical cystectomy.- 50. Robotic cystectomy and intracorporeal stoma formation.- 51. Orthotopic neobladders vs. ileal conduits.- 52. The role of enhanced recovery in robotic cystectomy.- 53. Robotic radical cystectomy and lymph node dissection.- 54. Robotic cystectomy and sentinel node mapping.- 55. Robotic radical cystectomy and intracorporeal stoma formation.- 56. Lap vs open vs robotic cystectomy.- 57. A systematic review on obesity in bladder cancer.- 58. Systematic review results on obesity in bladder cancer.- 59. Reviews on BMI and bladder cancer.- 60. Survivorship Issues in muscle invasive bladder cancer.- 61. Muscle invasive bladder cancer and health related quality of life.- 62. Body image in bladder cancer.- 63. The rationale for neoadjuvant chemotherapy.- 64. Support for partners in bladder cancer.